Accutane (Isotretinoin) Rare but Serious Side Effects: What the Evidence Actually Shows

Which serious risks does the label warn about?

The Absorica and Absorica LD prescribing information carries a boxed warning for embryo-fetal toxicity, then lists under Warnings and Precautions: psychiatric disorders, intracranial hypertension (pseudotumor cerebri), serious skin reactions, pancreatitis, lipid abnormalities, hearing impairment, hepatotoxicity, inflammatory bowel disease, musculoskeletal abnormalities, ocular abnormalities and hypersensitivity reactions [1]. The older Accutane label describes many of the same serious risks. Separately, the Absorica and Absorica LD label says those two products cannot be substituted milligram for milligram, because their bioavailability and recommended doses differ [1][2].

Birth defects: the risk behind the boxed warning

Isotretinoin is contraindicated in pregnancy. The boxed warning states there is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking any amount, even for short periods, and that potentially any exposed fetus can be affected [1]. Documented malformations involve the skull; the ears, including anotia, micropinna and small or absent external auditory canals; the eyes, including microphthalmia; facial dysmorphia and cleft palate; the central nervous system, including cerebral and cerebellar malformations, hydrocephalus, microcephaly and cranial nerve deficit; the cardiovascular system; the thymus; and the parathyroid glands [1]. IQ scores below 85 have been reported in exposed children, and an increased risk of spontaneous abortion and premature birth has been documented [1]. The warning gives no percentage, and states there are no accurate means of determining prenatally whether an exposed fetus has been affected [1].

This is what the iPLEDGE REMS exists for. Prescribers and pharmacies must be certified, every patient must be enrolled, and pharmacies dispense a maximum 30-day supply with a Medication Guide and no refills [1]. For patients who can get pregnant, the label requires a screening pregnancy test in a medical setting, a confirmatory test in a medical setting at least 30 days later and after at least 30 days of the chosen pregnancy prevention, and a pregnancy test within 7 days before each prescription [1]. Patients who cannot get pregnant are enrolled as well and must not share the drug or donate blood [1]. FDA approved changes to the REMS on 2026-02-09, including the option of at-home pregnancy tests during and after treatment with prescriber permission, while pre-treatment tests stay in a medical setting; FDA's page, current as of 2026-06-16, gives 2026-11-15 as the planned implementation date [3][4].

Psychiatric effects: the label warning and the studies

The label states that isotretinoin may cause depression, psychosis and, rarely, suicidal ideation, suicide attempts, suicide, and aggressive or violent behaviour [1]. It directs prescribers to ask patients and family members about psychiatric history before treatment and to assess for depression, mood disturbance, psychosis or aggression at each visit. It also instructs patients or caregivers to stop the drug immediately and promptly contact their health care provider if those symptoms develop, noting that discontinuation may be insufficient and further evaluation may be needed [1].

The published data point in different directions. A meta-analysis of 31 studies found that the change in depression scores from baseline was not significantly different between isotretinoin and alternative acne treatment (standardized mean difference −0.334, 95% CI −0.680 to 0.011), that the prevalence of depression after treatment declined (relative risk 0.588, 95% CI 0.382 to 0.904), and that mean depression scores fell from baseline (standardized mean difference −0.335, 95% CI −0.498 to −0.172); the authors noted that no randomized controlled trials were included and that variation between studies was large [5].

A retrospective Swedish register-based cohort of 5,756 patients prescribed isotretinoin between 1980 and 1989 identified 128 patients who were admitted to hospital for attempted suicide. For all attempts, the standardized incidence ratio was 1.57 (95% CI 0.86 to 2.63) in the year before treatment, 1.78 (95% CI 1.04 to 2.85) during treatment and up to six months after it, and 1.04 (95% CI 0.74 to 1.43) from three years after treatment stopped onward. The authors calculated a number needed to harm of 2,300 new six-month treatments per year for one additional first suicide attempt [6]. A cohort of 38 patients found depression severity decreased after two weeks of treatment, and that improvement tracked acne-related quality of life rather than acne grade [7].

Intracranial hypertension and tetracyclines

Isotretinoin use has been associated with cases of intracranial hypertension (pseudotumor cerebri), some of which involved concomitant use of tetracyclines, and the label says to avoid concomitant use of isotretinoin with tetracyclines [1]. The older label lists papilledema, headache, nausea and vomiting, and visual disturbances as early signs, and says patients with these symptoms should be screened for papilledema [2].

Pancreatitis and blood lipids

Marked elevations of serum triglycerides were reported in approximately 25% of patients receiving Accutane in clinical trials, about 15% developed a decrease in high-density lipoprotein and about 7% showed an increase in cholesterol; these lipid effects were reversible when the drug was stopped [2]. Triglyceride elevations above 800 mg/dL have been reported [2]. Acute pancreatitis has been reported in patients with either elevated or normal serum triglycerides, and in rare instances fatal hemorrhagic pancreatitis has been reported [2]. The label directs prescribers to stop treatment if hypertriglyceridemia cannot be controlled at an acceptable level or if symptoms of pancreatitis occur [1][2]. Cheilitis and hypertriglyceridemia were the two reactions the Absorica label describes as dose related [1].

Liver injury

Fasting lipid profile and liver function tests are required in all patients before treatment [1]. Hepatotoxicity is a Warnings and Precautions heading, with instructions to monitor liver function tests before and during treatment [1]. The adverse reactions section lists elevations of ALT, AST, GGTP, alkaline phosphatase, bilirubin and LDH, and hepatitis appears in the older label's adverse reaction list [1][2].

Inflammatory bowel disease

The Absorica label lists inflammatory bowel disease among its warnings and directs prescribers to discontinue treatment for abdominal pain, rectal bleeding or severe diarrhea [1]. A US nested case-control study of women aged 18 to 46 in a claims database matched 2,159 IBD cases with 43,180 controls and found an adjusted risk ratio for IBD with isotretinoin of 0.99 (95% CI 0.52 to 1.90); the pooled risk ratio across 5 studies in the accompanying meta-analysis was 0.94 (95% CI 0.65 to 1.36) [8]. The authors concluded the results do not suggest an increased risk of IBD, ulcerative colitis or Crohn disease [8].

Skin, eyes, hearing and bone

Postmarketing reports include erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis, which may be life-threatening, and the label says to monitor for these reactions and discontinue treatment if they occur [1][2]. The label also says to avoid wax epilation and skin resurfacing procedures such as dermabrasion and laser treatment during treatment and for at least 6 months afterward [1][2]. Hypersensitivity reactions, including anaphylaxis and other allergic reactions, are listed and are a contraindication [1].

For the eyes, listed reactions include corneal opacities, decreased night vision that may persist, cataracts, optic neuritis, photophobia and dry eyes, the last being among the most common reactions at 5% or more [1]. The label says that if visual symptoms occur, discontinue and refer for an ophthalmological exam [1]. The older label notes decreased tolerance to contact lenses during and after therapy [2]. Hearing impairment and tinnitus are listed, with instructions to discontinue and refer to specialized care for hearing impairment [1].

Musculoskeletal reactions include arthralgia, back pain, decreases in bone mineral density, premature epiphyseal closure, skeletal hyperostosis and calcification of tendons and ligaments [1]. About 16% of patients in a clinical trial developed musculoskeletal symptoms including arthralgia [2]. The label states that long-term use, even at low doses, has not been studied and is not recommended, and that the effect of long-term use on bone loss is unknown [1][2].

How often do these events actually happen?

The rates in the older label come from clinical trials: marked triglyceride elevation in about 25% of patients, an HDL decrease in about 15% and a cholesterol increase in about 7%, and musculoskeletal symptoms in about 16% of patients in a clinical trial [2]. Some other reactions were reported voluntarily after marketing, so their frequency cannot always be estimated reliably and a causal relationship cannot always be established [1].

FDA's adverse event database cannot fill that gap. FDA states that the existence of a report does not establish that the drug caused the event, and that the reports cannot be used to estimate how often an event occurs [9][10].

What the label requires before and during treatment

The label calls for a fasting lipid profile and liver function tests in all patients, and for pregnancy testing and pregnancy prevention through iPLEDGE for patients who can get pregnant, with enrollment for everyone [1]. Pharmacies dispense a maximum 30-day supply with a Medication Guide and no refills [1]. The label says patients must not donate blood during treatment and for one month after, because the blood could be given to a pregnant patient, and that breastfeeding is not recommended during treatment and for at least 8 days after the last dose [1]. It says to avoid vitamin A supplements and tetracyclines [1]. The older label also advises patients to avoid prolonged exposure to UV rays or sunlight [2].